Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1605786A induction study in moderately-to-severely active Crohn's disease
2011-002817-12Phase 3Terminated
- Sponsor
- GSK
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vercirnon in Crohn's disease (2 arms), sponsored by GSK. Primary endpoint: Clinical response at Week 12. Started Dec 2011; status: terminated.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-002817-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002817-12.